Today: 7 February 2026
Subscribe
Browse Category

Healthcare News 28 December 2025 - 2 January 2026

Spyre Therapeutics stock sinks 7% today: what’s pressuring SYRE and what investors watch next

Spyre Therapeutics stock sinks 7% today: what’s pressuring SYRE and what investors watch next

NEW YORK, Jan 2, 2026, 14:37 ET — Regular session Shares of Spyre Therapeutics, Inc. slid about 7% on Friday, falling to $30.48 in afternoon trading after touching a session low of $30.11. The stock opened at $32.76 and was last down $2.28 on the day. The move left Spyre underperforming the broader biotech tape, with the SPDR S&P Biotech ETF down about 0.7% and the iShares Nasdaq Biotechnology ETF off about 0.2%. “Money managers are waiting to see … the vibe for the coming year,” said Thomas Martin, senior portfolio manager at Globalt, describing the first-session tone in U.S.
2 January 2026
·····
Intuitive Surgical stock today: ISRG slips into 2026 as New Year’s Day shuts Wall Street

Intuitive Surgical stock today: ISRG slips into 2026 as New Year’s Day shuts Wall Street

NEW YORK, January 1, 2026, 16:48 ET — Market closed Shares of Intuitive Surgical, Inc. (ISRG) fell 1.1% to close at $566.36 on Wednesday, the final trading session of 2025, before U.S. stock markets closed for New Year’s Day. Yahoo Finance+1 The year-end dip matters now because the first trading days of January often bring portfolio rebalancing, and high-multiple healthcare names can be sensitive to shifts in risk appetite. For Intuitive, the next key test is whether its upcoming results and outlook keep investors confident in procedure-driven demand for robotic surgery. Wall Street ended 2025’s final session lower, with the
1 January 2026
····
Healthcare stocks today: FDA decisions jolt biotechs as Wall Street shuts for New Year

Healthcare stocks today: FDA decisions jolt biotechs as Wall Street shuts for New Year

NEW YORK, January 1, 2026, 13:41 ET — Market closed Vanda Pharmaceuticals’ FDA win in motion sickness set the tone for outsized, stock-specific swings in healthcare shares as Wall Street paused for the New Year’s Day holiday. U.S. stock markets were closed Thursday. Nasdaq The moves matter because regulatory calls can dominate small-cap biotech even when the broader healthcare sector trades like a defensive corner of the market. Investors also head into January watching how rates and earnings guidance reshape valuations after thin year-end trading. In Wednesday’s final session of 2025, the Health Care Select Sector SPDR Fund (XLV) fell
1 January 2026
······
UnitedHealth stock dips today as BlackCat ransomware guilty pleas revive cyber overhang

UnitedHealth stock dips today as BlackCat ransomware guilty pleas revive cyber overhang

NEW YORK, December 31, 2025, 1:03 ET — Regular session. UnitedHealth Group Incorporated shares fell 0.4% to $330.86 on Wednesday, extending a muted year-end session as investors weighed fresh legal developments tied to the ALPHV “BlackCat” ransomware gang. The stock traded between $330.32 and $333.24. The timing matters for UnitedHealth, which is heading into 2026 with investors focused on whether the insurer can keep a lid on costs while it works through a stack of operational and regulatory issues. That scrutiny tends to show up in the group’s pricing power and its medical care ratio — the share of premium
31 December 2025
····
Molina Healthcare stock rises again after Michael Burry touts insurer; Feb. 5 earnings in focus

Molina Healthcare stock rises again after Michael Burry touts insurer; Feb. 5 earnings in focus

NEW YORK, December 31, 2025, 10:30 ET — Regular session Molina Healthcare Inc shares were up 2.1% at $174.33 by 10:30 a.m. ET on Wednesday, after trading between $170.03 and $176.33 earlier in the session. The move matters because Molina has been highly sensitive to shifts in sentiment after cutting its 2025 profit outlook in October on higher medical costs, particularly in its Affordable Care Act marketplace business. “Approximately half of our underperformance is driven by the Marketplace business,” CEO Joseph Zubretsky said at the time. Reuters Investors are now looking to the company’s next update for signs that medical-cost
31 December 2025
·····
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

NEW YORK, December 31, 2025, 05:39 ET — Premarket Shares of Hims & Hers Health Inc (HIMS) fell 0.5% to $32.87 in premarket trading on Wednesday after closing down 3.1% at $33.04 in the prior session. The stock has traded between $23.97 and $72.98 over the past 52 weeks. Google The drift lower keeps attention on the telehealth group’s exposure to the fast-moving market for GLP-1 weight-loss drugs — a category that has become a major battleground for pricing, access and consumer demand. That matters now because GLP-1 drugs, a class of diabetes and obesity medicines that reduce appetite, are
31 December 2025
·······
UnitedHealth stock rises today as UNH outperforms peers ahead of Fed minutes, Jan. 27 results

UnitedHealth stock rises today as UNH outperforms peers ahead of Fed minutes, Jan. 27 results

NEW YORK, December 30, 2025, 11:18 ET — Regular session UnitedHealth Group Incorporated shares rose about 1.3% to $333.32 in late-morning trade on Tuesday, after swinging between $329.18 and $336.03. Humana gained about 0.5%, Elevance Health and Cigna edged higher, while CVS Health slipped; the Health Care Select Sector SPDR ETF was down about 0.1%. The move came as Wall Street drifted lower in thin holiday trading, with technology shares under pressure and U.S. markets set to close on Thursday for New Year’s Day. “I wouldn’t try to make too much out of anything that happens in a holiday-shortened week,”
30 December 2025
·····
Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

NEW YORK, December 29, 2025, 22:14 ET Novo Nordisk said it is lowering prices of its top-selling obesity drug Wegovy in China, after local outlet Yicai reported that list prices for the two highest doses were cut by 48% in the southwestern provinces of Yunnan and Sichuan. The new monthly list prices were 987 yuan ($141) and 1,284 yuan, Yicai said, citing local procurement authorities. Reuters The price move matters because China is fast becoming a pivotal growth market for weight-loss medicines, and pricing is now moving to the center of competition. Drugmakers are trying to lock in patients and
30 December 2025
····
Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit

Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit

NEW YORK, December 29, 2025, 22:17 ET — Market closed Gilead Sciences (GILD.O) shares were last up 0.15% at $124.91 on Monday, as investors weighed an analyst note that argued new Medicaid drug-pricing rules would have a limited financial impact on the company’s HIV franchise. Investing.com The call matters now because drugmakers and investors are still parsing a Trump administration pricing push that targets Medicaid and aims to bring U.S. medicine prices closer to those in other wealthy countries. Reuters For Gilead, the focus has been on whether “most-favored-nation” pricing — a policy that effectively ties prices to lower international
30 December 2025
·····
UnitedHealth stock slips as WSJ flags Optum mail-order refills ahead of 2026 guidance

UnitedHealth stock slips as WSJ flags Optum mail-order refills ahead of 2026 guidance

NEW YORK, December 29, 2025, 10:11 ET — Regular session UnitedHealth Group Incorporated shares edged lower on Monday after a Wall Street Journal investigation said mail-order pharmacies owned by major insurers, including UnitedHealth, dispensed billions of dollars of excess prescription drugs to Medicare patients. Wall Street Journal The report matters because it keeps a spotlight on Optum, UnitedHealth’s services arm, at a time when investors are focused on regulatory risk around Medicare and pharmacy practices and are looking for a clearer 2026 outlook from the company. Wall Street Journal+1 It also lands as UnitedHealth tries to reassure shareholders that internal
29 December 2025
····
Hims & Hers stock slides into year-end as investors weigh Ohio buildout and macro calendar

Hims & Hers stock slides into year-end as investors weigh Ohio buildout and macro calendar

NEW YORK, December 29, 2025, 01:59 ET — Market closed. Hims & Hers Health Inc shares last closed down about 1% at $34.31 on Friday, extending a four-session slide as U.S. markets headed into the final trading days of the year. Investing.com The move matters now because year-end trading typically brings lighter volumes and sharper swings, leaving growth stocks sensitive to shifts in rate expectations and risk appetite. Investopedia For Hims & Hers, investors have also been parsing how quickly the telehealth company can scale its physical operations as it pushes deeper into higher-touch care that relies on pharmacy and
29 December 2025
·····
Healthcare Stocks Today: Weekend Headlines, 2026 Themes, and What to Watch Before Monday’s Open

Healthcare Stocks Today: Weekend Headlines, 2026 Themes, and What to Watch Before Monday’s Open

NEW YORK, Dec. 28, 2025, 1:22 p.m. ET — Market closed (weekend). U.S. equity markets are shut for the weekend, but healthcare stocks are heading into Monday’s session with a fresh mix of catalysts—policy scrutiny around pharmacy practices, late-year sector rotation, and drug-development headlines—against a broader market backdrop that’s still flirting with major milestones. The S&P 500 has been within striking distance of 7,000, and strategists say the “path of least resistance” for stocks has remained higher absent a shock—an environment that can favor healthcare when investors look for diversification beyond the most crowded growth trades. Reuters Why healthcare stocks
28 December 2025
······
1 … 5 6 7 8 9 … 13

Stock Market Today

GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

7 February 2026
Aye Finance raised Rs 454.5 crore from 19 anchor investors ahead of its Feb 9 IPO, pricing shares at the top of a Rs 122–129 range. The company’s profit fell 40% to Rs 64.3 crore in the six months to September as bad loans rose to 4.85%. The IPO values Aye at about Rs 3,200 crore, below its last private round. Major investors include Nippon Life India and Goldman Sachs funds.
Go toTop